(Q36341849)

English

Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

title

Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma (English)

1 reference

stated in

Europe PubMed Central

13 August 2017

Owen A O'Connor

1

1 reference

stated in

Europe PubMed Central

13 August 2017

1 November 2005

1 reference

stated in

Europe PubMed Central

13 August 2017

Clinical Lymphoma and Myeloma

1 reference

stated in

Europe PubMed Central

13 August 2017

6

1 reference

stated in

Europe PubMed Central

13 August 2017

3

1 reference

stated in

Europe PubMed Central

13 August 2017

191-199

1 reference

stated in

Europe PubMed Central

13 August 2017

Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/0092-8674(86)90362-4

Identifiers

DOI

10.3816/CLM.2005.N.046

1 reference

stated in

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

PubMed ID

16354324

retrieved

13 August 2017

(Q36341849)

Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)